Physician profile
Tracy Tarvers
NPI 1093315848
$2,581.39
in general payments reported to CMS, 2019-2025
23 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $139 · 2023: $561 · 2024: $747 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,442.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.35 | 2022-2025 | |
| Novo Nordisk INC | $345.38 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $289.59 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $239.74 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $204.26 | 2023-2024 | Ingrezza |
| Amgen INC. | $128.69 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $69.12 | 2023-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $66.73 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $46.72 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.31 | 2023-2024 | Ofev, Synjardy, Tradjenta |
| Sumitomo Pharma America, INC. | $40.07 | 2023-2024 | Gemtesa |
| Verona Pharma, INC. | $34.91 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $33.75 | 2023-2024 | Arexvy, Shingrix |
| Vanda Pharmaceuticals INC. | $24.84 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.66 | 2024 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.41 | 2024 | Trulance, Xifaxan |
| Collegium Pharmaceutical, INC. | $20.04 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $18.54 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Lundbeck LLC | $17.97 | 2025 | Rexulti |
| Medtronic, INC. | $17.23 | 2025 | Interstim |
| Kowa Pharmaceuticals America, INC. | $16.95 | 2025 | Zoryve |
| Supernus Pharmaceuticals, INC. | $16.25 | 2025 | Qelbree |
| Xeris Pharmaceuticals, INC. | $12.88 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Tarvers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.